Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

Figure 5

Inhibition of the specific reactivity by mAb of HLA-class I and CD8. The specific reactivity of CD8+ T-cells was inhibited by mAb of HLA-class I and CD8. 51Cr-labeled 888 mel [gp100 (+), HLA-A24 (+)] pre-incubated with anti-class I MAb, anti-class II mAb, or a gp100-specific CTL clones (P3-2 or P3-3) were incubated with anti-CD4 mAb or anti-CD8 mAb for 1 hour at 4°C. After this time, effectors and target cells were mixed at an E/T ratio of 30 and cytotoxicity was determined after 4 hours incubation at 37°C. The cytotoxicity of the CTL clone against 888 mel was significantly reduced by the anti-class I and anti-CD8 mAbs.

Back to article page